Burning Rock Biotech (BNR) Accumulated Depreciation & Amortization (2021 - 2023)

Burning Rock Biotech has reported Accumulated Depreciation & Amortization over the past 3 years, most recently at $18.5 million for Q4 2023.

  • Quarterly results put Accumulated Depreciation & Amortization at $18.5 million for Q4 2023, up 6.18% from a year ago — trailing twelve months through Dec 2023 was $18.5 million (up 6.18% YoY), and the annual figure for FY2023 was $18.8 million, up 1.66%.
  • Accumulated Depreciation & Amortization for Q4 2023 was $18.5 million at Burning Rock Biotech, up from $17.4 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for BNR hit a ceiling of $18.5 million in Q4 2023 and a floor of $7.5 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 3 years was $17.4 million (2022), compared with a mean of $14.5 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 133.55% in 2022 and later increased 6.18% in 2023.
  • Burning Rock Biotech's Accumulated Depreciation & Amortization stood at $7.5 million in 2021, then soared by 133.55% to $17.4 million in 2022, then rose by 6.18% to $18.5 million in 2023.
  • The last three reported values for Accumulated Depreciation & Amortization were $18.5 million (Q4 2023), $17.4 million (Q4 2022), and $7.5 million (Q4 2021) per Business Quant data.